BioSpace News Archive

IDEAYA Biosciences, Inc. announced a first reported case of a uveal melanoma patient who was treated with single agent darovasertib as neoadjuvant therapy and was spared enucleation in an Investigator Sponsored Trial.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board.

Genelux Corporation announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.

TransCode Therapeutics, Inc. announced today publication of new data relevant to its lead therapeutic candidate, TTX-MC138, in the Journal of Clinical Oncology.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear Medicine and Molecular Imaging.

Compugen Ltd. today announced that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen’s potential first-in-class anti-PVRIG antibody, with COM902, Compugen’s potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today published its 2022 Sustainability Report, Caring at Ginkgo.

Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors.

Precision BioSciences Announces Oral Presentation of Positive ARCUS ® Gene Editing Data at International Liver Congress 2023.

Acasti Pharma Inc. today announced the appointment of W. Taylor Kimberly , MD, PhD, Alejandro A. Rabinstein, MD and Sherry H-Y. Chou, MD to its Scientific Advisory Board.